Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction

Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 2012-10, Vol.119 (10), p.S1-S12
Hauptverfasser: Foulks, Gary N., MD, FACS, Nichols, Kelly K., OD, PhD, Bron, Anthony J., FRCOphth, FMedSci, Holland, Edward J., MD, McDonald, Marguerite B., MD, FACS, Nelson, J. Daniel, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S12
container_issue 10
container_start_page S1
container_title Ophthalmology (Rochester, Minn.)
container_volume 119
creator Foulks, Gary N., MD, FACS
Nichols, Kelly K., OD, PhD
Bron, Anthony J., FRCOphth, FMedSci
Holland, Edward J., MD
McDonald, Marguerite B., MD, FACS
Nelson, J. Daniel, MD
description Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.
doi_str_mv 10.1016/j.ophtha.2012.06.064
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1112679347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0161642012006240</els_id><sourcerecordid>1112679347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</originalsourceid><addsrcrecordid>eNqFkU9P3DAQxS1UBAv0G1RVjj2Qrcf2OptLJcTflUBILT1bjj0BbxN7ayeg_fY4WsqBS6WRfJjfm_G8R8gXoHOgIL-v52HzNDzpOaPA5lTmEntkBgtRl6IC_onMMgalFIwekqOU1pRSKbk4IIeMUy64gBn5ueo3MTw7_1icveiIHlM6LVYW_eBaZ_Tggj8ttLfFnfb6EfvcKEJb3KFrQu-0L667qXuxTe3ozYSfkP1Wdwk_v73H5PfV5cP5TXl7f706P7stjYBqKBvLQVYNpa3RuBRWc66XTLR2ueCy4ryxtVkYaIAyxLqWgkoLXGvRNmzBtObH5Ntubj7g74hpUL1LBrv8HwxjUgDAZFVzUWVU7FATQ0oRW7WJrtdxq4CqyU21Vjs31eSmojKXyLKvbxvGpkf7LvpnXwZ-7ADMdz47jCoZh96gdRHNoGxw_9vwcYDpnM--d39wi2kdxuizhwpUyhr1a0p0ChRYzpIJyl8Bnleceg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112679347</pqid></control><display><type>article</type><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</creator><creatorcontrib>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</creatorcontrib><description>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2012.06.064</identifier><identifier>PMID: 23034341</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Cyclosporine - administration &amp; dosage ; Dry Eye Syndromes - diagnosis ; Dry Eye Syndromes - metabolism ; Eyelid Diseases - classification ; Eyelid Diseases - diagnosis ; Eyelid Diseases - metabolism ; Female ; Humans ; Keratomileusis, Laser In Situ ; Lacrimal Apparatus Diseases - diagnosis ; Lacrimal Apparatus Diseases - metabolism ; Male ; Meibomian Glands - pathology ; Middle Aged ; Ophthalmic Solutions - administration &amp; dosage ; Ophthalmology ; Tears - metabolism ; Visual Acuity</subject><ispartof>Ophthalmology (Rochester, Minn.), 2012-10, Vol.119 (10), p.S1-S12</ispartof><rights>American Academy of Ophthalmology</rights><rights>2012 American Academy of Ophthalmology</rights><rights>Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</citedby><cites>FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ophtha.2012.06.064$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23034341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foulks, Gary N., MD, FACS</creatorcontrib><creatorcontrib>Nichols, Kelly K., OD, PhD</creatorcontrib><creatorcontrib>Bron, Anthony J., FRCOphth, FMedSci</creatorcontrib><creatorcontrib>Holland, Edward J., MD</creatorcontrib><creatorcontrib>McDonald, Marguerite B., MD, FACS</creatorcontrib><creatorcontrib>Nelson, J. Daniel, MD</creatorcontrib><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</description><subject>Adult</subject><subject>Cyclosporine - administration &amp; dosage</subject><subject>Dry Eye Syndromes - diagnosis</subject><subject>Dry Eye Syndromes - metabolism</subject><subject>Eyelid Diseases - classification</subject><subject>Eyelid Diseases - diagnosis</subject><subject>Eyelid Diseases - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Keratomileusis, Laser In Situ</subject><subject>Lacrimal Apparatus Diseases - diagnosis</subject><subject>Lacrimal Apparatus Diseases - metabolism</subject><subject>Male</subject><subject>Meibomian Glands - pathology</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions - administration &amp; dosage</subject><subject>Ophthalmology</subject><subject>Tears - metabolism</subject><subject>Visual Acuity</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9P3DAQxS1UBAv0G1RVjj2Qrcf2OptLJcTflUBILT1bjj0BbxN7ayeg_fY4WsqBS6WRfJjfm_G8R8gXoHOgIL-v52HzNDzpOaPA5lTmEntkBgtRl6IC_onMMgalFIwekqOU1pRSKbk4IIeMUy64gBn5ueo3MTw7_1icveiIHlM6LVYW_eBaZ_Tggj8ttLfFnfb6EfvcKEJb3KFrQu-0L667qXuxTe3ozYSfkP1Wdwk_v73H5PfV5cP5TXl7f706P7stjYBqKBvLQVYNpa3RuBRWc66XTLR2ueCy4ryxtVkYaIAyxLqWgkoLXGvRNmzBtObH5Ntubj7g74hpUL1LBrv8HwxjUgDAZFVzUWVU7FATQ0oRW7WJrtdxq4CqyU21Vjs31eSmojKXyLKvbxvGpkf7LvpnXwZ-7ADMdz47jCoZh96gdRHNoGxw_9vwcYDpnM--d39wi2kdxuizhwpUyhr1a0p0ChRYzpIJyl8Bnleceg</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Foulks, Gary N., MD, FACS</creator><creator>Nichols, Kelly K., OD, PhD</creator><creator>Bron, Anthony J., FRCOphth, FMedSci</creator><creator>Holland, Edward J., MD</creator><creator>McDonald, Marguerite B., MD, FACS</creator><creator>Nelson, J. Daniel, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</title><author>Foulks, Gary N., MD, FACS ; Nichols, Kelly K., OD, PhD ; Bron, Anthony J., FRCOphth, FMedSci ; Holland, Edward J., MD ; McDonald, Marguerite B., MD, FACS ; Nelson, J. Daniel, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-bd3167b00fcae84da33a824fd8536733bd9c5c1b102ee996406d13aa4fb252aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Cyclosporine - administration &amp; dosage</topic><topic>Dry Eye Syndromes - diagnosis</topic><topic>Dry Eye Syndromes - metabolism</topic><topic>Eyelid Diseases - classification</topic><topic>Eyelid Diseases - diagnosis</topic><topic>Eyelid Diseases - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Keratomileusis, Laser In Situ</topic><topic>Lacrimal Apparatus Diseases - diagnosis</topic><topic>Lacrimal Apparatus Diseases - metabolism</topic><topic>Male</topic><topic>Meibomian Glands - pathology</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions - administration &amp; dosage</topic><topic>Ophthalmology</topic><topic>Tears - metabolism</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foulks, Gary N., MD, FACS</creatorcontrib><creatorcontrib>Nichols, Kelly K., OD, PhD</creatorcontrib><creatorcontrib>Bron, Anthony J., FRCOphth, FMedSci</creatorcontrib><creatorcontrib>Holland, Edward J., MD</creatorcontrib><creatorcontrib>McDonald, Marguerite B., MD, FACS</creatorcontrib><creatorcontrib>Nelson, J. Daniel, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foulks, Gary N., MD, FACS</au><au>Nichols, Kelly K., OD, PhD</au><au>Bron, Anthony J., FRCOphth, FMedSci</au><au>Holland, Edward J., MD</au><au>McDonald, Marguerite B., MD, FACS</au><au>Nelson, J. Daniel, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>119</volume><issue>10</issue><spage>S1</spage><epage>S12</epage><pages>S1-S12</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><abstract>Ocular surface disorders—and dry eye, in particular—is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23034341</pmid><doi>10.1016/j.ophtha.2012.06.064</doi></addata></record>
fulltext fulltext
identifier ISSN: 0161-6420
ispartof Ophthalmology (Rochester, Minn.), 2012-10, Vol.119 (10), p.S1-S12
issn 0161-6420
1549-4713
language eng
recordid cdi_proquest_miscellaneous_1112679347
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Cyclosporine - administration & dosage
Dry Eye Syndromes - diagnosis
Dry Eye Syndromes - metabolism
Eyelid Diseases - classification
Eyelid Diseases - diagnosis
Eyelid Diseases - metabolism
Female
Humans
Keratomileusis, Laser In Situ
Lacrimal Apparatus Diseases - diagnosis
Lacrimal Apparatus Diseases - metabolism
Male
Meibomian Glands - pathology
Middle Aged
Ophthalmic Solutions - administration & dosage
Ophthalmology
Tears - metabolism
Visual Acuity
title Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A43%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20Awareness,%20Identification,%20and%20Management%20of%20Meibomian%20Gland%20Dysfunction&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Foulks,%20Gary%20N.,%20MD,%20FACS&rft.date=2012-10-01&rft.volume=119&rft.issue=10&rft.spage=S1&rft.epage=S12&rft.pages=S1-S12&rft.issn=0161-6420&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2012.06.064&rft_dat=%3Cproquest_cross%3E1112679347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112679347&rft_id=info:pmid/23034341&rft_els_id=1_s2_0_S0161642012006240&rfr_iscdi=true